CGBIO_ID
CGBIO
Menu
  • Tentang CGBio
    • Perkenalan
    • Sambutan CEO
    • Sejarah Bisnis
    • Divisi Bisnis Global
    • Sejarah
  • Research and Development
    • Perkenalan Pusat Riset
    • Bidang Penelitian
    • Sertifikat dan patent
    • Publikasi Tesis
  • Informasi Produk
    • Keseluruhan
    • Ortopedi
    • Penyembuhan Luka
    • Estetik
    • Dental
  • ID
    • KOR
    • ENG
    • CN
    • JP
    • TH
    • ES
Open
Close
Sitemap
시지바이오 사이트맵 닫기
Tentang CGBio
Perkenalan
Sambutan CEO
Sejarah Bisnis
Divisi Bisnis Global
Sejarah
Research and
Development
Perkenalan Pusat Riset
Bidang Penelitian
Sertifikat dan patent
Publikasi Tesis
Informasi
Produk
Keseluruhan
Ortopedi
  • NOVOSIS
  • MEDICLORE
  • Bongener
  • Excelos Inject
  • Lumfix
  • NOVOMAX
Penyembuhan Luka
  • CURAVAC
  • CuraVAC SILVER
  • Curasys
  • EASYFOAM
  • EASYDERM PLUS THIN
  • EASYEF
Estetik
  • Cellunit
Dental
  • Novosis Dent
  • Bongener
  • Bongros
  • ExcelOS Inject
home

R & D

Wound

  • Perkenalan Pusat Riset
  • Bidang Penelitian
  • Sertifikat dan patent
  • Publikasi Tesis
Research Info
Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects
  • 2017-08-25
  • cgbio
  • 조회수Views : 632 views
NEXT
Prospective randomized comparison of scar appearances between cograft of acellular dermal matrix with autologous split-thickness skin and autologous split-thickness skin graft alone for full-thickness skin defects of the extremities
PREV
Evaluation of an antimicrobial silver foam dressing
LIST

Head Office : F3, 211, Itaewon-ro, Yongsan-gu, Seoul, Korea
Research Institute : 244, Galmachi-ro,Jungwon-gu,Seongnam-si, Gyeonggi-do,Korea
Head Office TEL. +82-2-550-8300

Copyright All Right Reserverd By CGbio

인스타그램 페이스북

  • Family site
    • DaewoongPhamercy
    • Daewoong Bio
    • DNC
    • Bio-Alpha

to be updated.

OK close